Abelacimab Demonstrates Safety, Superior Bleeding Reduction Compared With Rivaroxaban in Atrial Fibrillation | ASH Clinical News | American Society of Hematology
Khylia Marshall is a freelance journalist based in Tucson, Arizona. Patients with atrial fibrillation (AF) face an increased risk of stroke, yet many remain undertreated because of the bleeding risks associated with direct oral anticoagulants (DOACs), the current standard of care. However, results from the phase IIb, randomized AZALEA-TIMI 71 trial, published in the New England Journal of Medicine, suggest that abelacimab — a factor XI inhibitor — may offer a safer alternative. The study demonstrated
